公开(公告)号：US20220135550A1

公开(公告)日：2022-05-05

申请号：US17544490

申请日：2021-12-07

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Dean A. WACKER ,  Susheel Jethanand NARA ,  Srinivas CHERUKU ,  Kandhasamy SARKUNAM ,  Firoz Ali JAIPURI ,  Soodamani THANGAVEL ,  Srinivas JOGI ,  Pavan Kalyan KATHI

IPC: C07D413/12 ,  A61P11/00 ,  C07D271/06

Abstract: Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

公开(公告)号：US20190040080A1

公开(公告)日：2019-02-07

申请号：US15763281

申请日：2016-09-29

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Joanne J. BRONSON ,  Ling CHEN ,  Jonathan L. DITTA ,  Carolyn Diane DZIERBA ,  Prasada Rao JALAGAM ,  Guanglin LUO ,  John E. MACOR ,  Tarun Kumar MAISHAL ,  Susheel Jethanand Nara ,  Ramkumar RAJAMANI ,  Ramesh Kumar SISTLA ,  Soodamani THANGAVEL

IPC: C07D513/04 ,  A61P25/16 ,  A61P25/18 ,  A61P25/28

Abstract: The present disclosure is directed to biaryl compounds of formula (I) which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds and their use for treating e.g. pain, Alzheimer's disease, Parkinson's disease and schizophrenia.

公开(公告)号：US20210299126A1

公开(公告)日：2021-09-30

申请号：US17261954

申请日：2019-07-22

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： James Aaron BALOG ,  Jay A. MARKWALDER ,  Weifang SHAN ,  David K. WILLIAMS ,  Susheel Jethanand NARA ,  Saumya ROY ,  Soodamani THANGAVEL ,  Srinivas CHERUKU ,  Ramesh Kumar SISTLA

IPC: A61K31/506 ,  A61K39/395 ,  C07D403/10 ,  C07D403/14 ,  C07D413/10 ,  C07D417/10 ,  C07D213/75 ,  C07D401/14 ,  A61K31/4439 ,  A61K31/4418 ,  A61K31/496 ,  A61K31/501 ,  A61K31/519 ,  C07D405/14 ,  C07D487/04 ,  C07D417/14 ,  A61K31/5377 ,  A61K31/4725 ,  C07D413/14 ,  C07D213/74

Abstract: The present invention provides compounds of formula (I): wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases.